Research Progress of SGLT2 Inhibitors in Cancer Treatment by Miao X, Zhang J, Huang W, Wang Y, Jin A, Cao J, Zhao Z

Subjects: Get full text

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes by Diego Rivas‐Otero, Tomás González‐Vidal, Pablo Agüeria‐Cabal, Guillermo Ramos‐Ruiz, Paula Jimenez‐Fonseca, Carmen Lambert, Pedro Pujante Alarcón, Edelmiro Menéndez Torre, Miguel García‐Villarino, Elías Delgado Álvarez

Subjects: Get full text

Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI by Hiroyuki Uchinuma, Mitsunori Matsushita, Masaya Tanahashi, Hideki Suganami, Kazunori Utsunomiya, Kohei Kaku, Kyoichiro Tsuchiya

Subjects: Get full text

DRESS syndrome with the use of dapagliflozin: A case report and review of literature by Rebecca Badawi, Layal Akl, Karima Chafai, Jean-Louis Nguewa, Jean-François Gautier

Subjects: Get full text

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation by Christodoulos Dolapsakis, Emmanouil Karofylakis, Stamatios Chalvatzis

Subjects: “…sglt2 inhibitors…”
Get full text

Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin by Steffen Flindt Nielsen, Camilla Lundgreen Duus, Niels Henrik Buus, Jesper Nørgaard Bech, Frank Holden Mose

Subjects: Get full text

Is the Impact of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review by George I. Lambrou, Athanasia Samartzi, Eugenia Vlachou, Athanasios N. Tsartsalis

Subjects: Get full text

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis by Tabitha Kusi-Yeboah, Isaac Gianfrancesco, Muzammil Arif Din Abdul Jabbar, Phoebe Collins, Dalton James Bally, Juliet Thornton, Kieran Williams, Ayoola Ishola, Lucy Hong, Ping Jing Toong, Milindu Wickramarachchi

Subjects: “…SGLT2 inhibitors (SGLT2i)…”
Get full text

Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP‐STAR study by Hanako Nakajima, Hiroshi Okada, Akinori Kogure, Takafumi Osaka, Takeshi Tsutsumi, Masayoshi Onishi, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Shinichi Mogami, Akane Kitamura, Michiyo Ishii, Naoto Nakamura, Akio Kishi, Sato Eiko, Masahide Hamaguchi, Michiaki Fukui

Subjects: Get full text

The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies by Gang Fan, Hong Zuo, Lin Lin, Chao Xu, Rui Yan

Subjects: “…sglt2 inhibitor…”
Get full text

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus by Rujie Zheng, Wenjuan Song, Jie Lu, Mingyue Yuan, Xiaotong Sun, Chengzhi Lu

Subjects: “…SGLT2 inhibitors…”
Get full text

New Therapies on the Horizon for Preventing the Progression of Chronic Kidney Disease in Childhood by Siobhan Wagner, Isabella Tso, Damien Noone

Subjects: Get full text

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM by Birdie Huang, Chieh-Li Yen, Chao-Yi Wu, Chung-Ying Tsai, Jia-Jin Chen, Ching-Chung Hsiao, Yung-Chang Chen, I-Chang Hsieh, Huang-Yu Yang

Subjects: Get full text

Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator by Celestino Sardu, Maria Consiglia Trotta, Ludovica Vittoria Marfella, Giovambattista D’Amico, Carmine La Marca, Ciro Mauro, Matteo Santamaria, Valerio Giordano, Fabrizio Turriziani, Concetta Rafaniello, Ferdinando Carlo Sasso, Paolo Calabro, Carmine Pizzi, Raffaele Marfella, Annalisa Capuano, Giuseppe Paolisso

Subjects: “…SGLT2i…”
Get full text

¿Combinamos AR-GLP1 + i-SGLT2? Sí o no by Claudia Folino

Subjects: Get full text

Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study by Ji Yun Lee, Ju-Hyun Lee, Eun-Jung Jung, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang

Subjects: “…SGLT-2 inhibitors…”
Get full text

Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG) by Amin Roshdy Soliman, Mohamed Elkhatib, Sahier El-Khashab, Rasha Ahmed Darwish, Ahmed Fayed, Tarek S. Abdelaziz, Hany Hammad, Rabab Mahmoud Ahmed, Hoda Abdelhamid Maamoun

Subjects: “…SGLT2 inhibitors…”
Get full text

EVALUAREA EFICACITĂȚII TERAPIEI CU INHIBITORI SGLT2 LA PACIENȚII CU INSUFICIENȚĂ CARDIACĂ CU FRACȚIE DE EJECȚIE PĂSTRATĂ by Tatiana Cotonet, Irina Cabac-Pogorevici

Subjects: Get full text

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors by Filip Rolski, Michał Mączewski

Subjects: Get full text

Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses... by O. Y. Sukhareva, Z. T. Zuraeva, M. S. Shamhalova

Subjects: Get full text